Alexander Vos is the Chief Executive Officer (CEO) of VectorY Therapeutics, a developer of novel gene therapies using vectorized antibodies to treat CNS and neuromuscular disorders. From October 2018 until May 2021, he was Chief Executive Officer of VarmX, a manufacturer of therapeutic proteins that instantaneously restore blood clotting in bleeding patients. Since 1989 Alexander has held executive roles in biopharmaceutical and contract manufacturing organizations, including CEO of PharmaCell BV, which he helped turn into a leading European contract manufacturing organization focused on cell and gene therapy that was subsequently acquired by Lonza AG; Deputy CEO and chief operating officer of PAION AG (Frankfurt Stock Exchange; PA8), a pharmaceutical company headquartered in Aachen, Germany; CEO of MediService AG, a leading specialty pharmacy services company in Europe that was sold to Galenica AG; and executive roles at Genzyme Europe BV, a pharmaceutical manufacturer headquartered in The Netherlands.
From September 2018 until May 2021, Alexander served as chairman of the board of directors of private equity–backed Symeres BV (formerly Mercachem-Syncom), a leading European, mid-sized contract research organization that offers innovative best-in-class chemistry solutions. He is a member of the supervisory board of CiMaas BV, a company focused on developing cellular immunotherapy for specific oncology indications. From October 2015 to May 2018, Alexander was a member of the board of directors of the Alliance for Regenerative Medicine, the global advocate for regenerative and advanced therapies, based in Washington, DC. He worked for the pharmaceutical practice of McKinsey & Company from 1989 to 1994.
Alexander holds a master’s degree in pharmacy and pharmacology from the University of Amsterdam and an MBA from Stanford University Graduate School of Business.